DBV Technologies (NASDAQ:DBVT) Shares Cross Above Fifty Day Moving Average – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s share price crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.91 and traded as high as $4.46. DBV Technologies shares last traded at $4.39, with a volume of 6,288 shares.

Analysts Set New Price Targets

A number of research firms have commented on DBVT. StockNews.com assumed coverage on shares of DBV Technologies in a research note on Tuesday. They issued a “hold” rating for the company. HC Wainwright upped their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Trading Up 0.9 %

The company has a market cap of $90.30 million, a P/E ratio of -0.98 and a beta of 0.67. The business’s 50 day simple moving average is $3.91 and its 200 day simple moving average is $3.85.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.